Fermer le menu


Member of Lyonbiopole


ENYO Pharma is a privately held clinical stage biopharmaceutical R&D company. Our lead compound Vonafexor modulates NR1H4 which is mainly expressed in the gut, the liver and the kidney.

We develop currently Vonafexor in Phase 2 against a rare kidney diseases, Alport Syndrome and are exploring other ones (e.g. ADPKD,…). Another analog, EYP651, is currently in Phase 1 and profiled against larger renal diseases like CKD or DKD.

ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.


Strategic application domain: Human Medicine

Application market: Infectious Diseases, Metabolic Disorders - Endocrinology, Rare disease

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide, (Bio) Informatics & software, Small Molecules

Created on jan. 14th, 2014 - 10 employees



60 Avenue Rockefeller,
BIOSERRA 1 - Bâtiment B
69008 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.